HF
FBRX icon

HRT Financial’s Forte Biosciences FBRX Stock Holding History

HRT Financial’s Portfolio FBRX Stock Details FBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-1,270
Closed -$1.09M – 3045
2021
Q1 		$1.09M Buy
1,270
+1,036
+443% +$848K 0.01% 1039
2020
Q4 		$213K Buy
+234
New +$220K ﹤0.01% 1471
2020
Q2 		– Sell
-33
Closed -$15K – 1600
2020
Q1 		$15K Buy
+33
New +$12.9K ﹤0.01% 682

Other funds holding FBRX

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
FAM
Fred Alger Management New York $22.8B AUM 64.63% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
CCC
Cable Car Capital San Francisco, California $289M AUM 26.33% 1-Year Est. Return

HRT Financial's FBRX Position: Q2 2021 in Review

HRT Financial sold out of Forte Biosciences (FBRX) in Q2 2021, closing a stake of 1,270 shares — an estimated $1.09M sold.

HRT Financial first reported a position in FBRX in Q1 2020 and held it in 3 quarters. The position peaked at $1.09M in Q1 2021. 75 funds tracked by Wall St. Rank hold FBRX as of Q2 2021.

  • HRT Financial reported no remaining Forte Biosciences position as of Q2 2021 after selling out during the quarter.
  • HRT Financial sold 1,270 Forte Biosciences shares in Q2 2021, an estimated $1.09M.
  • HRT Financial first reported a position in Forte Biosciences in Q1 2020 and held it in 3 quarters.
  • HRT Financial's Forte Biosciences position peaked at $1.09M in Q1 2021.
  • 75 funds tracked by Wall St. Rank held Forte Biosciences as of Q2 2021.

Based on HRT Financial's 13F filing for Q2 2021, filed 16 Aug 2021.